Monoclonal antibody (MAb) ICR41.1i (rat IgG2a) is specific for a conformation-dependent epitope of human immunodeficiency virus type 1 (HIV-1) V3, and MAb F58 (mouse IgG1) recognizes the peptide IXXGPGR, at the tip of the V3 loop. Both MAbs neutralized HIV-1 strain IIIB in C8166 and HeLa-T4(CD4) cells. Neutralization by either MAb did not inhibit attachment of virus to target cells as determined by FAGS analysis, ELISA or immunofluorescence, and such attachment was absolutely dependent on the availability of CD4 molecules. F58 inhibited virus-induced cell-cell fusion, and reduced internalization of virions in direct proportion to neutralization, In contrast, ICR41.1i had no effect on HIV-1-mediated cell fusion or on internalization of virus...
In contrast to infrequent and low-titer cross-neutralization of human immunodeficiency virus type 1 ...
AbstractThree mouse monoclonal antibodies (mAb) were produced against soluble recombinant vaccinia v...
Production of cross-reactive antibodies recognizing the V3 loop--that is, the principal neutralizing...
Neutralization of human immunodeficiency virus type 1 by adding antibody after the virus has attache...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the "principal neutrali...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the “principal neutrali...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the “principal neutrali...
Abstract The V3 region of both HIV-1 gp120 and HIV-2 gp125 surface glycoprotein has been described a...
A number of linear and conformation-dependent neutralizing monoclonal antibodies (MAbs) have been ma...
Only two virus-neutralizing peptide microantibodies (MicroAbs) have been described and little is kno...
The major target of the neutralizing antibody response to infection by the human immunodeficiency vi...
Antibody-mediated neutralization of human immunodeficiency virus type-1 (HIV-1) is thought to functi...
To increase insight into the structural basis of CXCR4 utilization in human immunodeficiency virus t...
In contrast to infrequent and low-titer cross-neutralization of human immunodeficiency virus type 1 ...
AbstractThree mouse monoclonal antibodies (mAb) were produced against soluble recombinant vaccinia v...
Production of cross-reactive antibodies recognizing the V3 loop--that is, the principal neutralizing...
Neutralization of human immunodeficiency virus type 1 by adding antibody after the virus has attache...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the "principal neutrali...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the “principal neutrali...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the “principal neutrali...
Abstract The V3 region of both HIV-1 gp120 and HIV-2 gp125 surface glycoprotein has been described a...
A number of linear and conformation-dependent neutralizing monoclonal antibodies (MAbs) have been ma...
Only two virus-neutralizing peptide microantibodies (MicroAbs) have been described and little is kno...
The major target of the neutralizing antibody response to infection by the human immunodeficiency vi...
Antibody-mediated neutralization of human immunodeficiency virus type-1 (HIV-1) is thought to functi...
To increase insight into the structural basis of CXCR4 utilization in human immunodeficiency virus t...
In contrast to infrequent and low-titer cross-neutralization of human immunodeficiency virus type 1 ...
AbstractThree mouse monoclonal antibodies (mAb) were produced against soluble recombinant vaccinia v...
Production of cross-reactive antibodies recognizing the V3 loop--that is, the principal neutralizing...